⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898846 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL23388242 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL1163329 | 0.81 | LMNA (0.32) | — | |
| SCHEMBL3757533 | 0.79 | HPGD (0.36) | — | |
| SCHEMBL30230989 | 0.78 | — | — | |
| SCHEMBL28043336 | 0.78 | HPGD (0.39) | — | |
| SCHEMBL23851226 | 0.76 | HSD11B1 (0.31) | — | |
| SCHEMBL21835422 | 0.76 | HSD11B1 (0.31) | — | |
| SCHEMBL23851224 | 0.76 | HSD11B1 (0.31) | — | |
| SCHEMBL22556942 | 0.76 | L3MBTL3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661875-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167950-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| EP-4368620-A1 | COMPOUND SERVING AS KAT6 INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024019597-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING THE SAME | 주식회사 넥스트젠바이오사이언스 | 2024-01-25 | — | — | WO | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2018158298-A1 | CRYSTALLINE FORMS OF (2R)-N-HYDROXY-4-(6-((1-(2-HYDROXYETHYL)AZETIDIN-3-YL)BUTA-1,3 DIYN-1 YL)-3 OXO-1H PYRROLO[1,2 C]IMIDAZOL-2(3H)-YL)-2-METHYL-2 (METHYLSULFONYL)BUTANAMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-07 | — | — | WO | disclosed |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-3052485-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| CN-105324380-A | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-02-10 | — | — | CN | disclosed |
| CN-105246890-A | Pyrrolo[2, 3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-01-13 | — | — | CN | disclosed |
| WO-2015051244-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |